Niagen Bioscience, Inc. (NAGE) News
Follow Niagen Bioscience, Inc. (NAGE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Niagen Bioscience Q3 2026 Earnings Call Begins
Niagen Bioscience's quarterly earnings call has begun.
EQUITY | Nov 04, 2026, 09:27 PM UTC
M
Niagen Bioscience Reports Third-Quarter 2026 Financial Results
Niagen Bioscience reported financial results for the third quarter of 2026; the supplied body is truncated before any figures or details.
EQUITY | Nov 04, 2026, 09:05 PM UTC
M
Niagen Bioscience Expects 2026 E-Commerce Growth of About 5%
The company expects 2026 direct website revenue growth of 15% to 20% year over year, while its remaining consumer business is expected to offset e-commerce growth.
EARNINGS | Nov 04, 2026, 09:02 PM UTC
M
NAGE Q3'26 Earnings Preview: Revenue Estimate
Niagen Bioscience is set to report Q3'26 results November 4 after the market closes. Revenue and EPS estimates were provided.
EQUITY | Oct 28, 2026, 11:05 AM UTC
M
Niagen Bioscience to Report Third-Quarter 2026 Results November 4
Niagen Bioscience said it will report third-quarter 2026 financial results on Wednesday, November 4, 2026.
EQUITY | Oct 15, 2026, 12:36 PM UTC
L
Niagen Bioscience, Inc. (NAGE) Signs Start-Up Pact With MGB for Large NR Trial
Niagen Bioscience signed a Start-Up Agreement with Mass General Brigham to plan what it envisions as the largest, most comprehensive randomized, placebo-controlled trial of Niagen (NR) in adults 50+, with final design el
NEWS | Sep 30, 2026, 12:32 PM UTC
L
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) t
NEWS | Sep 30, 2026, 12:32 PM UTC
H
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
Niagen Bioscience (NASDAQ: NAGE ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire ca
LIVE | Sep 30, 2026, 10:55 AM UTC
L
NAGE - Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
NAGE - Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves
NEWS | Sep 21, 2026, 12:42 PM UTC
L
NAGE - Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
NAGE - Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
NEWS | Sep 17, 2026, 12:33 PM UTC
L
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
EQUITY | Sep 10, 2026, 12:32 PM UTC
L
Niagen Bioscience to present at Canaccord Genuity’s Well Summit
Niagen Bioscience said CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity’s Well Summit.
EQUITY | Sep 10, 2026, 12:32 PM UTC
L
NAGE - Niagen Bioscience to Present at Longevity Investors Conference
NAGE - Niagen Bioscience to Present at Longevity Investors Conference
EQUITY | Sep 02, 2026, 12:35 PM UTC
L
Niagen Bioscience management to present at Longevity Investors Conference
Niagen Bioscience, Inc. (NAGE) said senior management will participate in the Longevity Investors Conference from September 14 to 17, 2026, in Gstaad.
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
NAGE: Strong growth, innovation, and clinical progress position the company as a leader in NAD therapeutics
NAGE: Strong growth, innovation, and clinical progress position the company as a leader in NAD therapeutics
EQUITY | Aug 27, 2026, 09:22 PM UTC
L
NAGE: Strong financials and innovation in NAD therapies drive growth and clinical progress
NAGE: Strong financials and innovation in NAD therapies drive growth and clinical progress
EQUITY | Aug 27, 2026, 08:44 PM UTC
L
NAGE - Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
NAGE - Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
EQUITY | Aug 26, 2026, 12:35 PM UTC
L
Niagen Bioscience to present at Nasdaq X LD Micro SF summit
Niagen Bioscience says it will present at the Nasdaq X LD Micro inaugural SF summit.
EQUITY | Aug 26, 2026, 12:32 PM UTC
M
Niagen Bioscience expands Tru Niagen retail footprint with GNC, Sam's Club
Niagen Bioscience says it is expanding Tru Niagen's retail footprint through GNC and Sam's Club.
EQUITY | Aug 20, 2026, 12:41 PM UTC
L
NAGE to Present at Midwest IDEAS Conference
NAGE is presenting at the 17th Annual Midwest IDEAS Investor Conference
EQUITY | Aug 12, 2026, 12:33 PM UTC
L
NAGE - Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
NAGE - Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:12 PM UTC
L
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ: NAGE ) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.
EARNINGS | Aug 04, 2026, 08:06 PM UTC
M
NAGE Selects Evotec For NB4168 Development
NAGE partners with Evotec for preclinical development
EQUITY | Aug 03, 2026, 12:41 PM UTC
L
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
EQUITY | Jul 27, 2026, 12:34 PM UTC
L
Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
() -- Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. The E
REGULATION | Jul 13, 2026, 01:04 PM UTC
L
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
Niagen Bioscience formally launched the first drug candidate of NAD Pharmaceuticals, its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily
EQUITY | Jul 08, 2026, 12:39 PM UTC